Verastem (VSTM) CFO receives 57-share stock award in Form 4

Rhea-AI Filing Summary

Calkins Daniel reported acquisition or exercise transactions in this Form 4 filing.

Verastem, Inc.’s Chief Financial Officer Daniel Calkins received a grant of 57 shares of common stock on March 20, 2026 at a value of $5.74 per share. This was a compensation-related award, not an open-market purchase. Following the grant, he directly holds 121,327 common shares.

Insider Trade Summary 10b5-1

1 transaction reported

Mixed 1 txn

Insider Calkins Daniel

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	57	$5.74	$327.18

Holdings After Transaction: Common Stock — 121,327 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Calkins Daniel

(Last) (First) (Middle)

C/O VERASTEM, INC.,

117 KENDRICK ST., SUITE 500

(Street)

NEEDHAM MASSACHUSETTS 02494

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Verastem, Inc. [ VSTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		A		57(1)	D	$5.74	121,327	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.

	/s/ Daniel Calkins	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Verastem (VSTM) report for its CFO?

Verastem reported that CFO Daniel Calkins received a grant of 57 common shares on March 20, 2026. The award was recorded at $5.74 per share and is a compensation-related acquisition, not an open-market stock purchase.

How many Verastem (VSTM) shares does the CFO hold after this Form 4?

After the reported transaction, Verastem CFO Daniel Calkins directly holds 121,327 common shares. The Form 4 shows this total following the 57-share grant, providing context for the relatively small size of the new award.

Was the Verastem (VSTM) CFO’s Form 4 transaction a stock purchase or compensation grant?

The transaction was a compensation-related grant, coded as an award acquisition rather than an open-market purchase. It reflects 57 common shares granted at $5.74 per share, consistent with equity-based executive compensation practices.

What is the size of the Verastem (VSTM) CFO’s latest stock award?

The latest stock award to Verastem’s CFO totals 57 common shares of Verastem, Inc. common stock. The shares are valued at $5.74 each in the filing, making this a relatively small, routine equity compensation grant.

Does the Verastem (VSTM) CFO Form 4 show any insider stock sales?

The structured Form 4 data shows only an acquisition of 57 common shares as a grant to the CFO. It does not report any open-market stock sales or derivative exercises in this specific filing.